261 related articles for article (PubMed ID: 34503422)
21. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
23. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
25. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
27. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
28. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
30. CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells.
Nilmani ; D'costa M; Bothe A; Das S; Udhaya Kumar S; Gnanasambandan R; George Priya Doss C
Adv Protein Chem Struct Biol; 2023; 135():125-177. PubMed ID: 37061330
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
32. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Chen P; Lee NV; Hu W; Xu M; Ferre RA; Lam H; Bergqvist S; Solowiej J; Diehl W; He YA; Yu X; Nagata A; VanArsdale T; Murray BW
Mol Cancer Ther; 2016 Oct; 15(10):2273-2281. PubMed ID: 27496135
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
34. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Law ME; Corsino PE; Narayan S; Law BK
Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
[TBL] [Abstract][Full Text] [Related]
35. Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Palomino-Schätzlein M; Pineda-Lucena A
Methods Mol Biol; 2016; 1336():211-23. PubMed ID: 26231718
[TBL] [Abstract][Full Text] [Related]
36. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
37. Promising Anticancer Activity of Multitarget Cyclin Dependent Kinase Inhibitors against Human Colorectal Carcinoma Cells.
Manohar SM; Joshi KS
Curr Mol Pharmacol; 2022; 15(7):1024-1033. PubMed ID: 35068399
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
40. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
